Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.48 CAD | 0.00% | -4.00% | +62.71% |
Apr. 25 | NurExone Biologic Announces OTCQB Listing And DTC Eligibility | MT |
Apr. 02 | NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 12
Managers
Managers | Title | Age | Since |
---|---|---|---|
Lior Shaltiel
CEO | Chief Executive Officer | - | 21-03-31 |
Eran Ovadya
DFI | Director of Finance/CFO | - | 22-06-14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jay Richardson
BRD | Director/Board Member | 78 | 22-01-02 |
Gadi Riesenfeld
BRD | Director/Board Member | 79 | 23-07-05 |
Yoram Drucker
CHM | Chairman | 59 | 19-12-31 |
Oded Orgil
BRD | Director/Board Member | 57 | 22-06-14 |
Lior Shaltiel
CEO | Chief Executive Officer | - | 21-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 65,830,428 | 61,850,428 ( 93.95 %) | 0 | 93.95 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.71% | 23.11M | |
+59.79% | 62.59B | |
-2.30% | 41.18B | |
+44.36% | 40.29B | |
-8.29% | 27.9B | |
+12.84% | 26.21B | |
-21.64% | 19.09B | |
+6.00% | 13.08B | |
+24.33% | 12.26B | |
+27.24% | 12.05B |
- Stock Market
- Equities
- NRX Stock
- Company NurExone Biologic Inc.